- Reaction score
- 1,663
A drug molecule "invented" by artificial intelligence (AI) will be used in human trials in a world first for machine learning in medicine.
It was created by British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma.
The drug will be used to treat patients who have obsessive-compulsive disorder (OCD).
Typically, drug development takes about five years to get to trial, but the AI drug took just 12 months.
Exscienta chief executive Prof Andrew Hopkins described it as a "key milestone in drug discovery".
He told the BBC: "We have seen AI for diagnosing patients and for analysing patient data and scans, but this is a direct use of AI in the creation of a new medicine."
The molecule - known as DSP-1181 - was created by using algorithms that sifted through potential compounds, checking them against a huge database of parameters.
It was created by British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma.
The drug will be used to treat patients who have obsessive-compulsive disorder (OCD).
Typically, drug development takes about five years to get to trial, but the AI drug took just 12 months.
Exscienta chief executive Prof Andrew Hopkins described it as a "key milestone in drug discovery".
He told the BBC: "We have seen AI for diagnosing patients and for analysing patient data and scans, but this is a direct use of AI in the creation of a new medicine."
The molecule - known as DSP-1181 - was created by using algorithms that sifted through potential compounds, checking them against a huge database of parameters.
Artificial intelligence-created medicine to be used on humans for first time
A British start-up has developed a new drug much more quickly than traditional methods by using AI.
www.bbc.com
Last edited by a moderator: